Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Glioblastoma Multiforme
Interventions
DRUG

PQR309

80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide

Trial Locations (1)

8091

University Hospital Zurich, Neurology, Zurich

Sponsors
All Listed Sponsors
collaborator

University Hospital, Basel, Switzerland

OTHER

collaborator

Insel Gruppe AG, University Hospital Bern

OTHER

collaborator

University Hospital, Zürich

OTHER

lead

PIQUR Therapeutics AG

INDUSTRY